Daniel Pollyea, MD
University of Colorado, Denver
5
5
3
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Beata Holkova, MD
Massey Cancer Center
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Sarit Assouline, MD
Jewish General Hospital
Shared therapeutic areas:
Gregory Reid, MSc, MBA
MethylGene Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
All 5 trials loaded